Announcements Trials
Browse Landscape

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Vascular Diseases 2Heart Diseases 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Second Primary 1Metabolic Diseases 1Heart Failure 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Cancer Metastatic 1Cardiovascular Diseases 1Cardiotoxicity 1Cancer Therapy-related Cardiovascular Toxicity 1Breast Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Etoposide 23Cisplatin 15Carboplatin 13Irinotecan 12apatinib 11anlotinib 10durvalumab 7Topotecan 6toripalimab 4surufatinib 4sintilimab 4atezolizumab 4Temozolomide 4Drug Therapy 4tislelizumab 3lobaplatin 3camrelizumab 3Simvastatin 3Radiotherapy 3Ifosfamide 3Albumin-Bound Paclitaxel 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2olaparib 2niraparib 2isophosphamide mustard 2avelumab 2X-Rays 2Platinum 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Small Cell Lung Carcinoma × Antineoplastic Agents × Clear all
NCT04663438 2020-12-11

Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

Peking Union Medical College Hospital

Unknown
300 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡